Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Torii Pharmaceutical Co Ltd
4551Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; CORECTIM, a topical janus kinase (JAK) inhibitor; and allergen immunotherapy tablets comprising CEDARCURE and MITICURE. In addition, it is engaged in real estate rental business. The company markets its products primarily through medical representatives for medical professionals. The company has a collaboaration with ALK-Abelló A/S to develop, market and distribute ALK's allergy immunotherapy tablet for the treatment of grass pollen allergy. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc. Address: Torii Nihonbashi Bldg., Tokyo, Japan, 103-8439
Analytics
Precio Objetivo de WallStreet
622 741.89 JPYRelación P/E
24.0543Rentabilidad por dividendo
2.84 %Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave 4551
Análisis de dividendos 4551
Aumento del dividendo durante 5 años
150 %Crecimiento continuo
2 añoRatio de pago medio en 5 años
49 %Tendencia del payout 4551
Valoración de la acción 4551
Finanzas 4551
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |